Novel Assay for Rapid Antibody Screening

描述(由申请人提供)：Primorigen Biosciences将利用第一阶段SBIR资金开发一种无框架、多路复用的微阵列筛选系统，用于快速鉴定和表征与目标蛋白质具有适当亲和力和特异性的抗体匹配对。该系统改进了分析内容，极大地减少了多路微阵列开发的时间和成本。这一新系统的核心是Primorigen用于多路分析的新型无框架微阵列设备，该设备允许直接在平面阵列表面针对几个结合目标测试96个(或384个)样品。结果，可以高精度地检测数百个样本中的数十个蛋白质，每个实验产生数千个数据点，提高了筛选的速度。虽然新系统可以检测任何蛋白质，但这个第一阶段的项目将专注于检测人类胰岛β细胞标志物，这些标志物有助于鉴定可能成为治疗或治愈1型糖尿病候选的胰岛素分泌细胞系。第一阶段项目将开发一种无框架硝化纤维素分析表面，并使用微型阵列方法来筛选和表征检测目标蛋白的抗体。第二阶段将a)验证这些分析用于商业用途，b)开发制造方案，c)将该系统应用于细胞分化标记物。

DESCRIPTION (provided by applicant): Primorigen Biosciences will use Phase I SBIR funds to develop a frameless, multiplexed, microarray screening system for rapid identification and characterization of antibody matched pairs with appropriate affinity and specificity for target proteins. This system produces improved assay content and dramatically reduces the time and cost of multiplexed microarray development. The core of this new system is Primorigen's novel frameless microarray device for multiplexed analysis that allows testing of 96 (or 384) samples against several binding targets directly on a flat array surface. As a result, dozens of proteins in hundreds of samples can be detected with high precision to generate thousands of data points per experiment, increasing speed of screening. While the new system can be adapted to detect any protein, this Phase I project will focus on detecting human pancreatic beta cell markers useful for characterizing insulin-secreting cell lines that may be candidates to treat or cure Type 1 diabetes. The Phase I project will develop a frameless nitrocellulose assay surface and use the miniaturized array methods to screen and characterize antibodies that detect the target proteins. Phase II will a) validate these assays for commercial use, b) develop manufacturing protocols, and c) apply this system to cell differentiation markers.